127 related articles for article (PubMed ID: 1651303)
1. Comparison of surgery and radiation therapy for non-small cell carcinoma of the lung with mediastinal metastasis.
Durci ML; Komaki R; Oswald MJ; Mountain CF
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):629-36. PubMed ID: 1651303
[TBL] [Abstract][Full Text] [Related]
2. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
3. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center.
Komaki R; Roth JA; Walsh GL; Putnam JB; Vaporciyan A; Lee JS; Fossella FV; Chasen M; Delclos ME; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):347-54. PubMed ID: 10974447
[TBL] [Abstract][Full Text] [Related]
4. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation.
Komaki R; Mountain CF; Holbert JM; Garden AS; Shallenberger R; Cox JD; Maor MH; Guinee VF; Samuels B
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):31-6. PubMed ID: 2380092
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer.
Firat S; Bousamra M; Gore E; Byhardt RW
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1047-57. PubMed ID: 11958901
[TBL] [Abstract][Full Text] [Related]
6. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials.
Cox JD; Scott CB; Byhardt RW; Emami B; Russell AH; Fu KK; Parliament MB; Komaki R; Gaspar LE
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):505-9. PubMed ID: 10078629
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
8. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
9. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
10. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
Johnstone DW; Byhardt RW; Ettinger D; Scott CB
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
[TBL] [Abstract][Full Text] [Related]
11. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
12. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Movsas B; Scott C; Sause W; Byhardt R; Komaki R; Cox J; Johnson D; Lawton C; Dar AR; Wasserman T; Roach M; Lee JS; Andras E
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1143-9. PubMed ID: 10613306
[TBL] [Abstract][Full Text] [Related]
13. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection.
Taylor NA; Liao ZX; Cox JD; Stevens C; Roth J; Walsh G; Chang JY; Guerrero T; Jeter M; Putnam J; Fossella FV; Allen P; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):204-12. PubMed ID: 14697440
[TBL] [Abstract][Full Text] [Related]
14. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival.
Werner-Wasik M; Scott C; Cox JD; Sause WT; Byhardt RW; Asbell S; Russell A; Komaki R; Lee JS
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1475-82. PubMed ID: 11121651
[TBL] [Abstract][Full Text] [Related]
15. [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis].
Huang GJ; Fang DK; Cheng GY; Zhang DC
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):62-4. PubMed ID: 16737625
[TBL] [Abstract][Full Text] [Related]
16. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.
Taylor NA; Liao ZX; Stevens C; Walsh G; Roth J; Putnam J; Fossella F; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):616-25. PubMed ID: 12788166
[TBL] [Abstract][Full Text] [Related]
17. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Bonomi P; Gale M; Rowland K; Taylor SG; Purl S; Reddy S; Lee MS; Phillips A; Kittle CF; Warren W
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):247-52. PubMed ID: 1846847
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
20. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.
Misthos P; Sepsas E; Kokotsakis J; Skottis I; Lioulias A
Ann Thorac Surg; 2008 Nov; 86(5):1626-30. PubMed ID: 19049761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
